75413-98-8

Usage

Uses

Used in Pharmaceutical Industry:
6-(tert-butyl)-1,2,3,4-tetrahydroquinoline is used as a building block for the synthesis of biologically active molecules due to its diverse pharmacological properties, such as antimicrobial, antimalarial, and anticancer activities. The presence of the tert-butyl group may improve the compound's effectiveness and stability, making it a valuable component in the development of new drugs.
Used in Organic Synthesis:
6-(tert-butyl)-1,2,3,4-tetrahydroquinoline is used as an important compound in organic synthesis for its potential to create a variety of biologically active molecules. Its unique structure allows it to be a key component in the preparation of complex organic compounds.
Used as a Catalyst or Ligand in Chemical Reactions:
6-(tert-butyl)-1,2,3,4-tetrahydroquinoline is utilized as a catalyst or ligand in various chemical reactions owing to its unique structure and properties. This application can enhance the efficiency and selectivity of chemical processes, making it a valuable tool in the field of chemistry.

InChI:InChI=1/C13H19N/c1-13(2,3)11-6-7-12-10(9-11)5-4-8-14-12/h6-7,9,14H,4-5,8H2,1-3H3

Upstream product

• 68141-13-9 6-(tert-butyl)quinoline 
• 769-92-6 4-tert-Butylaniline 
• 3282-56-2 4-tert-butylnitrobenzene 

Downstream Products

• 1448426-97-8 1-(4-(6-tert-butyl-3,4-dihydroquinolin-1(2H)-ylsulfonyl)phenyl)pyrrolidin-2-one 

Relevant academic research and scientific papers

Homogeneous pressure hydrogenation of quinolines effected by a bench-stable tungsten-based pre-catalyst

We report on an operationally simple catalytic method for the tungsten-catalyzed hydrogenation of quinolines through the use of the easily handled and self-contained precursor [WCl(η5-Cp)(CO)3]. This half sandwich complex is indefinitely storable on the bench in simple screw-capped bottles or stoppered flasks and can, if required, be prepared on a multi-gram scale while the actual catalytic transformations were performed in the presence of a Lewis acid in order to achieve both decent substrate conversions and product yields. The described method represents a facile and atom-efficient access to a variety of 1,2,3,4-tetrahydroquinolines that circumvents the use of cost-intensive and oxygen-sensitive phosphine ligands as well as auxiliary hydride reagents.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

Selectivity in the Hydrogenation of 6- and 8-Substituted-quinolines

Quinoline (1) and the 6- or 8-substituted-quinolines (2)-(14) (R = Me, Pri, But, Ph, OMe, OH, CF3, or F) were hydrogenated catalytically on platinum under either weakly basic (solvent MeOH) or strongly acidic (solvent CF3CO2H) conditions.In methanol the only product was the corresponding 1,2,3,4-tetrahydro-compound.In trifluoroacetic acid, compounds hydrogenated in the benzene ring were isolated as major products; both electron-withdrawing and electron-donating substituents at C-6 or C-8 cause (sometimes drastic) reduction in yield.The products were characterized by their 1H and 13C n.m.r. spectra.